{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:03:26Z","timestamp":1758845006479,"version":"3.44.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.urology.2020.04.043","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T22:00:16Z","timestamp":1587160816000},"page":"316-318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The Changing Landscape of Upper Tract Urothelial Carcinoma Management"],"prefix":"10.1016","volume":"145","author":[{"given":"Xiaosong","family":"Meng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Roehrborn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitaly","family":"Margulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2020.04.043_bib0001","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.eururo.2017.07.036","article-title":"European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update","volume":"73","author":"Roupr\u00eat","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.04.043_bib0002","unstructured":"Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract\u202f: a 30-year experience in 252 patients. 1944;4295:1-8."},{"key":"10.1016\/j.urology.2020.04.043_bib0003","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","article-title":"Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration","volume":"115","author":"Margulis","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2020.04.043_bib0004","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.urology.2012.12.059","article-title":"Comparative analysis of oncologic outcomes of partial ureterectomy vs radical nephroureterectomy in upper tract urothelial carcinoma","volume":"81","author":"Bagrodia","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.urology.2020.04.043_bib0005","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1464-410X.2012.11649.x","article-title":"Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy","volume":"112","author":"Xylinas","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2020.04.043_bib0006","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.eururo.2010.06.029","article-title":"Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy","volume":"58","author":"Kaag","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.04.043_bib0007","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.04260415","article-title":"Chronic renal insufficiency cohort study (CRIC): overview and summary of selected findings","author":"Denker","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.urology.2020.04.043_bib0008","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2020.04.043_bib0009","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1464-410X.2007.06705.x","article-title":"The modern management of upper tract urothelial cancer: surgical treatment","volume":"99","author":"Arancibia","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2020.04.043_bib0010","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1097\/PAS.0b013e3181aec42a","article-title":"Small endoscopic biopsies of the ureter and renal pelvis","volume":"33","author":"Tavora","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"4, Supplement","key":"10.1016\/j.urology.2020.04.043_bib0011","first-page":"e1166","article-title":"LBA26 phase ii trial of neoadjuvant chemotherapy followed by extirpative surgery for patients with High Grade Upper Tract Urothelial Carcinoma (HG UTUC): results from ECOG-ACRIN 8141","volume":"199","author":"Hoffman-Censits","year":"2018","journal-title":"J Urol"},{"issue":"6_suppl","key":"10.1016\/j.urology.2020.04.043_bib0012","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.6_suppl.407","article-title":"Results of POUT: a phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC)","volume":"36","author":"Birtle","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urology.2020.04.043_bib0013","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2020.04.043_bib0014","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.urology.2020.04.043_bib0015","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2020.04.043_bib0016","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1016\/S0140-6736(17)32365-6","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial","volume":"390","author":"Petrylak","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.urology.2020.04.043_bib0017","doi-asserted-by":"crossref","DOI":"10.1002\/path.5318","article-title":"Molecular pathology of the luminal class of urothelial tumors","author":"Bernardo","year":"2019","journal-title":"J Pathol"},{"key":"10.1016\/j.urology.2020.04.043_bib0018","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.urology.2020.04.043_bib0019","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.eururo.2008.08.008","article-title":"Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (Lynch Syndrome) tumor spectrum","volume":"54","author":"Roupr\u00eat","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2020.04.043_bib0020","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/jmg.2010.076992","article-title":"Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers","volume":"47","author":"Van Der Post","year":"2010","journal-title":"J Med Genet"},{"key":"10.1016\/j.urology.2020.04.043_bib0021","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/01.ju.0000086551.22844.cd","article-title":"Microsatellite instability in urothelial carcinoma of the upper urinary tract","volume":"170","author":"Amira","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2020.04.043_bib0022","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science (80-)"},{"key":"10.1016\/j.urology.2020.04.043_bib0023","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2020.04.043_bib0024","first-page":"21","article-title":"Thermo reversible hydrogel based delivery of mitomycin C (UGN-101) for treatment of upper tract urothelial carcinoma (UTUC)","volume":"5","author":"Kleinmann","year":"2019","journal-title":"Bl Cancer"},{"issue":"Supplement 4","key":"10.1016\/j.urology.2020.04.043_bib0025","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1097\/01.JU.0000557508.23335.0a","article-title":"Lba-16 nephron-sparing management of low grade (Lg) utuc with ugn-101 (mitomycin gel) for instillation: the olympus trial experience","volume":"201","author":"Kleinmann","year":"2019","journal-title":"J Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429520304246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429520304246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T02:15:49Z","timestamp":1758766549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429520304246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":25,"alternative-id":["S0090429520304246"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2020.04.043","relation":{},"ISSN":["0090-4295"],"issn-type":[{"type":"print","value":"0090-4295"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Changing Landscape of Upper Tract Urothelial Carcinoma Management","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2020.04.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}